

-continued

<220> FEATURE:

<223> OTHER INFORMATION: oligonucleotide

<400> SEQUENCE: 39

actcctgctt gctgatccac

20


What is claimed is:

1. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a TiPARP agonist.

2. The method of claim 1, wherein the TiPARP agonist is an aryl hydrocarbon receptor (AHR) agonist or an estrogen receptor (ER) agonist.

3. The method of claim 1, wherein the TiPARP agonist interacts with TiPARP directly.

4. The method of claim 1, wherein the TiPARP agonist is a tamoxifen compound within the following generic formula:



wherein:

R¹ and R² are independently selected from alkyl groups containing one to three carbon atoms, or alternatively, R¹ and R² may interconnect to form a five-membered or six-membered heterocycloalkyl ring;


R³, R⁴, and R⁵ are independently selected from hydrogen atom, halogen atom, methyl, ethyl, hydroxy (OH), methoxy (—OCH₃), and ethoxy (—OCH₂CH₃);

R¹¹, R¹², and R¹³ are independently selected from hydrogen atom, hydroxy, and methoxy groups;

X is a hydrogen atom or halogen atom; and


p is 2 or 3.

5. The method of claim 4, wherein the tamoxifen compound has the following structure:



6. The method of claim 5, wherein R¹ and R² are independently selected from alkyl groups containing one to three carbon atoms.

7. The method of claim 6, wherein R¹ and R² are methyl groups, which corresponds to the following structure:



8. The method of claim 7, wherein R³ and R⁵ are hydrogen atoms and R⁴ is selected from the group consisting of halogen atom, methyl, ethyl, hydroxy (OH), methoxy (—OCH₃), and ethoxy (—OCH₂CH₃).

9. The method of claim 7, wherein R³, R⁴, and R⁵ are hydrogen atoms, which corresponds to the following structure: